Pages that link to "Q30422060"
Jump to navigation
Jump to search
The following pages link to Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study (Q30422060):
Displaying 43 items.
- Predictive accuracy of amyloid imaging for progression from mild cognitive impairment to Alzheimer disease with different lengths of follow-up: a meta-analysis. [Corrected (Q27007436) (← links)
- Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease (Q27009411) (← links)
- Development of positron emission tomography β-amyloid plaque imaging agents (Q27012742) (← links)
- Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation (Q27303745) (← links)
- Spreading of pathology in neurodegenerative diseases: a focus on human studies (Q28082279) (← links)
- Toward the treatment and prevention of Alzheimer's disease: rational strategies and recent progress (Q30419992) (← links)
- Mild to moderate Alzheimer dementia with insufficient neuropathological changes (Q33592693) (← links)
- Communicating mild cognitive impairment diagnoses with and without amyloid imaging (Q33640373) (← links)
- Amyloid imaging with carbon 11-labeled Pittsburgh compound B for traumatic brain injury (Q33856185) (← links)
- A distinct subfraction of Aβ is responsible for the high-affinity Pittsburgh compound B-binding site in Alzheimer's disease brain (Q34381799) (← links)
- Molecular imaging of Alzheimer disease pathology (Q34651135) (← links)
- Increased CSF Aβ during the very early phase of cerebral Aβ deposition in mouse models (Q35904243) (← links)
- Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta (Q36526176) (← links)
- Correspondence between in vivo (11)C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques (Q36592191) (← links)
- Postmortem 3-D brain hemisphere cortical tau and amyloid-β pathology mapping and quantification as a validation method of neuropathology imaging. (Q36944895) (← links)
- Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association (Q37069527) (← links)
- Amyloid-β positron emission tomography imaging probes: a critical review (Q37086266) (← links)
- Identification of promethazine as an amyloid-binding molecule using a fluorescence high-throughput assay and MALDI imaging mass spectrometry (Q37185672) (← links)
- Reference region automatic extraction in dynamic [(11)C]PIB (Q37298297) (← links)
- Washout allometric reference method (WARM) for parametric analysis of [(11)C]PIB in human brains (Q37346940) (← links)
- Cerebral amyloid PET imaging in Alzheimer's disease (Q37459083) (← links)
- Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection (Q37498339) (← links)
- Imaging the role of amyloid in PD dementia and dementia with Lewy bodies (Q38228098) (← links)
- Multimodal imaging in Alzheimer's disease: validity and usefulness for early detection (Q38576124) (← links)
- Molecular and cellular pathophysiology of preclinical Alzheimer's disease (Q38836004) (← links)
- Biomarkers for the Early Detection and Progression of Alzheimer's Disease (Q38979999) (← links)
- Proteopathic Strains and the Heterogeneity of Neurodegenerative Diseases. (Q39022241) (← links)
- Five-year follow-up of 11C-PIB uptake in Alzheimer's disease and MCI. (Q39343733) (← links)
- Biomarkers in Neurodegenerative Diseases (Q39413097) (← links)
- Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease (Q41140682) (← links)
- Comparative pathobiology of β-amyloid and the unique susceptibility of humans to Alzheimer's disease (Q41971448) (← links)
- Amyloid PET imaging: applications beyond Alzheimer's disease (Q43161462) (← links)
- Appropriate use criteria for amyloid PET imaging cannot replace guidelines: on behalf of the European Association of Nuclear Medicine (Q44414803) (← links)
- Down syndrome: age-dependence of PiB binding in postmortem frontal cortex across the lifespan (Q46847955) (← links)
- Amyloid fibril polymorphism - a challenge for molecular imaging and therapy (Q47717455) (← links)
- Generation of Clickable Pittsburgh Compound B for the Detection and Capture of β-Amyloid in Alzheimer's Disease Brain (Q47728790) (← links)
- Down syndrome, beta-amyloid and neuroimaging (Q48102481) (← links)
- Docosahexaenoic acid reduces ER stress and abnormal protein accumulation and improves neuronal function following traumatic brain injury. (Q48340159) (← links)
- Perspectives in molecular imaging using staging biomarkers and immunotherapies in Alzheimer's disease (Q51481172) (← links)
- Negative 11C-PIB PET Predicts Lack of Alzheimer's Disease Pathology in Postmortem Examination. (Q55398477) (← links)
- Impact of partial volume correction on the regional correspondence between in vivo [C-11]PiB PET and postmortem measures of Aβ load. (Q55710456) (← links)
- Multisite study of the relationships between antemortem [C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology (Q57809100) (← links)
- Neuropathological correlates of amyloid PET imaging in Down syndrome (Q92399659) (← links)